GLPwatch
Papers (10378)
Page 92 of 173, ranked by citation count.
- Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT.
- 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
- Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.
- Numaswitch: an efficient high-titer expression platform to produce peptides and small proteins.
- Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
- Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
- Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study.
- iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
- Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data.
- Journal withdraws article after complaints from drug manufacturers.
- Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
- Semaglutide: should the media slim down its enthusiasm?
- Practical guidance for use of oral semaglutide in primary care: a narrative review.
- Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
- Extending our understanding of exenatide: a rare case of angio-oedema.
- Liraglutide protects against diabetes mellitus complicated with focal cerebral ischemic injury by activating mitochondrial ATP-sensitive potassium channels.
- Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.
- Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.
- Augmented nephroprotective effect of liraglutide and rabeprazole via inhibition of OCT2 transporter in cisplatin-induced nephrotoxicity in rats.
- Exendin-4 Plays a Protective Role in a Rat Model of Spinal Cord Injury Through SERCA2.
- GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response.
- Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
- Tirzepatide: a novel therapeutic approach for Alzheimer's disease.
- Liraglutide for weight loss in obese people.
- C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study.
- Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
- Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.
- Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.
- The transcription factor B-cell lymphoma (BCL)-6 modulates pancreatic {beta}-cell inflammatory responses.
- Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health.
- A Rare Case of Tirzepatide-Induced Hepatotoxicity.
- Primary and Secondary Binding of Exenatide to Liposomes.
- The interaction between human serum albumin and antidiabetic agent - exenatide: determination of the mechanism binding and effect on the protein conformation by fluorescence and circular dichroism techniques - Part I.
- Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.
- Comparative Efficacy of Semaglutide Versus Liraglutide or Efinopegdutide on Weight Loss in Obese Patients: A Systematic Review and Meta-Analysis.
- Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease.
- Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
- Exenatide and feeding: possible peripheral neuronal pathways.
- Antihyperglycemic Medications and Cardiovascular Risk Reduction.
- Effects of Metformin on Renal Function, Cardiac Function, and Inflammatory Response in Diabetic Nephropathy and Its Protective Mechanism.
- Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats.
- Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double-blind trial.
- Titration and discontinuation of semaglutide for weight management in commercially insured US adults.
- Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study.
- Semaglutide injection for the treatment of adults with type 2 diabetes.
- A Probable Case of Tirzepatide-Induced Acute Pancreatitis.
- Duodenal-jejunal bypass changes the composition of the gut microbiota.
- β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.
- The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus.
- Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
- The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.
- GLP-1 agonists and the gut microbiome: A bidirectional relationship.
- Mechanisms and treatment of obesity-related hypertension-Part 2: Treatments.
- Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
- Liraglutide in Children and Teens with Type 2 Diabetes.
- On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide.
- Successful Implementation of a Multidisciplinary Weight Loss Program Including GLP1 Receptor Agonists for Liver Transplant Candidates With High Body Mass Index.
- Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.
- Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis.
- Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report.